EMA — authorised 20 November 2014
- Marketing authorisation holder: Merck Sharp & Dohme Limited
- Status: approved
🇪🇺 Zontivity in European Union
EMA authorised Zontivity on 20 November 2014
Marketing authorisations
EMA — authorised 19 January 2015
- Application: EMEA/H/C/002814
- Marketing authorisation holder: Merck Sharp Dohme Limited
- Local brand name: Zontivity
- Indication: Zontivityis indicated for the reduction of atherothrombotic events in adult patients with a history of myocardial infarction (MI), ,co-administered with acetylsalicylic acid (ASA) and, where appropriate, clopidogrel; or symptomatic peripheral arterial disease (PAD), co-administered with acetylsalicylic acid (ASA) or, where appropriate, clopidogrel.
- Status: withdrawn
Zontivity in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Neuroscience approved in European Union
Frequently asked questions
Is Zontivity approved in European Union?
Yes. EMA authorised it on 20 November 2014; EMA authorised it on 19 January 2015.
Who is the marketing authorisation holder for Zontivity in European Union?
Merck Sharp & Dohme Limited holds the EU marketing authorisation.